Risks & Controversies
Cocoa, conscience, and changing diets
Beyond the commodity cycle, Hershey carries a cluster of ethical, legal and demand-side risks — from West African child labor and heavy metals in dark chocolate to weight-loss drugs and a regulatory push on additives.
Cocoa child-labor litigationLead/cadmium suitsGLP-1 · dyes · price fatigue
The headline risk is cocoa (see The Cocoa Shock), but Hershey also faces supply-chain ethics (West African child-labor litigation)[31], product-safety suits over lead/cadmium in dark chocolate[33], and demand shifts from GLP-1 drugs and health regulation[36]. None has dented US dominance yet — but each is live.
Cocoa supply-chain ethics
Chocolate's West African cocoa has long been linked to child and forced labor. A federal class action filed in February 2021 by International Rights Advocates (Coubaly v. Nestlé, Cargill, Mars, Mondelez, Hershey and two others) was brought by eight Malian citizens who alleged they were trafficked as children onto Ivorian cocoa farms; a trial judge ruled for the companies in June 2022 and a federal appeals court affirmed the dismissal in July 2025, but advocacy continues, including a separate effort to force the US government to block cocoa harvested with child labor[31][32]. Hershey publicizes sustainable-sourcing commitments, but critics say the industry has missed its own pledges to end child labor — a persistent reputational risk rather than (so far) a financial one.
Heavy metals in dark chocolate
A 2022 Consumer Reports study found measurable lead and cadmium in all 28 dark-chocolate bars it tested, and class actions (including via Milberg) allege Hershey failed to disclose heavy metals in its dark chocolate[33]. The science is contested — trace metals occur naturally in cocoa and from soil — but the litigation and headline risk are real.
Changing diets and regulation
Two demand-side shifts loom. GLP-1 weight-loss drugssuppress appetite for sweets; Hershey calls the effect a “mild impact” today[36]— and is even a partial beneficiary, as “Ozempic breath” lifted Ice Breakers mint sales ~8% in early 2026[35]. Separately, the federal “MAHA” push to phase out synthetic food dyes prompted Hershey to commit to removing synthetic dyes from its candy and snacks by the end of 2027[34].
SWOT
Strengths
- •Dominant US franchise: ~44–46% of US chocolate, iconic brands (Reese's, Hershey's, Kisses), and the perpetual US Kit Kat licence (s1, s11, s40).
- •Record FY2025 net sales of $11.69B (+4.4%) and a successful salty-snacks build-out (SkinnyPop #1 RTE popcorn, Dot's #2 pretzels) (s2, s13).
- •Stable, mission-aligned control via the Hershey Trust insulates management from short-term raiders and funds the Milton Hershey School (s21, s22).
Weaknesses
- •Extreme concentration: ~81% of sales in North America Confectionery and only ~8% International — exposed to one category and one market (s10, s16).
- •Cocoa dependence: a single commodity drove a 60% profit collapse in 2025 despite record sales (s26, s28).
- •Sub-scale internationally versus Mondelez, Nestlé and Mars — limited global growth optionality (s16, s29).
Opportunities
- •Cocoa normalization plus prior pricing flowing through underpins a guided 2026 recovery (adj. EPS +30–35%) (s3, s20).
- •Snacking expansion (salty + better-for-you, e.g. LesserEvil) and GLP-1-driven mint/gum demand diversify the mix (s13, s35, s38).
- •Health repositioning (removing synthetic dyes by 2027) can defuse regulatory/MAHA pressure and refresh the portfolio (s34).
Threats
- •Structural cocoa volatility from a multi-year West-African supply deficit (s17, s37).
- •Reputational/legal exposure on cocoa child labor and heavy metals (lead/cadmium) in dark chocolate (s31, s33).
- •Demand headwinds from GLP-1 drugs, price-fatigued shoppers, and a mature US chocolate category (s36, s42).
Source ids (e.g. s2, s31) refer to the Sources page; each SWOT item is backed in the section prose across this study.
🚩The bear's strongest point
A US-concentrated chocolate company tied to one volatile commodity, facing supply-chain litigation, product- safety suits, weight-loss-drug headwinds and a maturing category — that is a real cluster of risks the brand strength has so far absorbed but not eliminated
[28][36].
Why the risks may be manageable
- +Cocoa is easing and 2026 EPS is guided to recover sharply[3].
- +Child-labor litigation has been dismissed in US courts to date[31].
- +Hershey is adapting — removing dyes, benefiting from GLP-1 mint demand[34][35].
Why the risks may bite
- −Cocoa volatility is structural and could persist[37].
- −Heavy-metals and supply-chain issues are ongoing reputational/legal risks[33][32].
- −GLP-1 drugs and price fatigue could pressure volumes in a mature category[36][42].
The weighing
Each section of this study lays out both cases; this is where the study weighs them. Four questions decide the Hershey story. Here is where the evidence leans on each, how confident that lean is, and — concretely — what would flip it.
On whether the cocoa shock is a blip or the new normal: the evidence leans toward an earnings recovery on a structurally higher, more volatile cocoa baseline (medium confidence). The controlling evidence is the 2026 guide — adjusted EPS +30–35%, reported EPS +79–89%[3] — and the fact that sales re-accelerated through the worst of the shock (Q3 2025 +6.5%, outlook raised)[27], which outweighs the case for permanent profit impairment because pricing has already passed through without breaking volumes — FY2025 sales hit a record[2]. The strongest surviving counter-argument: the deficit that drove the spike was the largest in over 60 years and rests on aging trees, disease and climate[17][37] — supply problems one good harvest does not fix. What would flip this reading: FY2026 adjusted EPS growth below the 30% bottom of the guide at the Q4 2026 report (early February 2027); or cocoa futures sustained back above ~$10,000/ton. Pre-mortem: if this looks wrong in two years, the most likely reason is that one easing season was mistaken for normalization — or, on the other side, that pricing power plus the ~$900M productivity program[19] was underrated.
On whether the Trust is a fortress or a cage:the evidence leans toward a fortress that will hold — and therefore a foregone control premium shareholders should treat as permanent (high confidence). The controlling evidence is three blocked approaches across two decades — 2002, Mondelez's ~$23B bid in 2016, and the December 2024 approach[23]— and the Trust's perpetual mandate to fund the Milton Hershey School[22], which outweighs the market's revealed appetite (the stock spiked on the 2024 takeover report alone[39]) because ~80% of the votes[21], not the market, decide. The strongest surviving counter-argument: the Trust is itself supervised — Pennsylvania's attorney general has oversight, and past board controversies forced reforms[41]— so the structure is not beyond challenge. What would flip this reading: a Trust announcement of Class B conversion or a stake-diversification sale; or a Pennsylvania-AG-driven settlement altering control. Pre-mortem: if this looks wrong in two years, the most likely reason is a future Trust board diversifying under fiduciary pressure — or, on the other side, assuming the cage costs nothing when independence is what preserves the perpetual US Kit Kat license[11].
On whether snacking can offset the chocolate core:the evidence leans no — not yet; chocolate still sets the company's fate (high confidence on today's mix, medium on the trajectory). The controlling evidence is the segment arithmetic — salty snacks were $1,135.7M of $11,202.3M FY2024 sales (~10%) against $9,118.6M of North America Confectionery (~81%)[10] — and the cocoa shock itself, which cut net income 60% despite the snacks arm[28]; together they outweigh the brand-rank wins (SkinnyPop #1, Dot's #2)[13] because earnings mix follows revenue share, not category rank. The strongest surviving counter-argument: the build-out keeps compounding — LesserEvil was added in November 2025[38] — and the segment grows faster than the core[13]. What would flip this reading: salty snacks above ~15% of net sales in the FY2027 segment disclosure; or a multi-billion-dollar diversifying acquisition under new CEO Kirk Tanner[5]. Pre-mortem: if this looks wrong in two years, the most likely reason is that niche wins were extrapolated into needle-moving scale too generously — or, on the other side, that a bigger, faster M&A pivot was missed.
On how heavy the ESG and health overhangs are:the evidence leans toward reputational and legal overhang rather than a financial event — so far (medium confidence; this is the most genuinely open of the four). The controlling evidence is the child-labor suit's dismissal, affirmed on appeal in July 2025[31], and record FY2025 sales booked with every overhang already public[2], which outweighs the sheer size of the risk cluster because none of it has yet shown up in demand or the P&L. The strongest surviving counter-argument: GLP-1 is the one with structural teeth — Hershey itself concedes the drugs are changing snacking habits[36] — and the heavy-metals suits are live[33]. What would flip this reading: Hershey upgrading its GLP-1 language beyond “mild impact” on a 2026–27 earnings call; an adverse heavy-metals ruling or labeling mandate; or child-labor litigation surviving a motion to dismiss. Pre-mortem: if this looks wrong in two years, the most likely reason is treating GLP-1 adoption as static while it compounds — or, on the other side, over-weighting headlines consumers keep shrugging off (Ice Breakers sales rose ~8% on “Ozempic breath”)[35].
⚖️The shape of the verdict
Weighed together: a dominant, takeover-proof US franchise whose earnings are recovering from a commodity shock that permanently raised its cost baseline; a diversification program that is working but not yet decisive; and an overhang cluster that is real but so far reputational. The recovery question carries the most weight and the least certainty — which is why its tripwires (the 2026 guide, cocoa back above ~$10,000/ton) are the ones to watch first
[3][37].